Compare YORW & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YORW | RXST |
|---|---|---|
| Founded | 1816 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.0M | 524.6M |
| IPO Year | N/A | 2021 |
| Metric | YORW | RXST |
|---|---|---|
| Price | $32.44 | $10.93 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.30 |
| AVG Volume (30 Days) | 84.7K | ★ 807.7K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | $76,882,000.00 | ★ $142,085,000.00 |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $7.69 | $4.26 |
| P/E Ratio | $23.34 | ★ N/A |
| Revenue Growth | 3.63 | ★ 10.75 |
| 52 Week Low | $29.68 | $6.32 |
| 52 Week High | $36.48 | $37.13 |
| Indicator | YORW | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 46.56 | 44.85 |
| Support Level | $33.11 | $10.46 |
| Resistance Level | $32.99 | $13.14 |
| Average True Range (ATR) | 0.60 | 0.66 |
| MACD | -0.13 | -0.28 |
| Stochastic Oscillator | 4.21 | 20.29 |
The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and eleven wastewater collection and treatment systems. The company operates within its franchised territory, which covers more than 57 municipalities within four counties in south-central Pennsylvania.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.